Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELLO-1: Tazemetostat with Enzalutamide or Abiraterone in mCRPC
NCT04179864Phase 2Terminated
- Sponsor
- Epizyme, Inc.
- Start
- Nov 2019
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of tazemetostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Epizyme, Inc. Primary endpoints: Treatment-Emergent Adverse Events at 149 weeks, Recommended Phase 2 Dose at 28 days and 1 more. Started Nov 2019; status: terminated.
02
Drugs
tazemetostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04179864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179864.